Completed Trials

LUD 2015-005: ANTI-PD-L1 in combination with chemo(radio)therapy for oesophageal cancer

SCALOP-2: Systemic therapy and Chemoradiation in Advanced Localised Pancreatic cancer–2

CHARIOT: M6620 plus standard treatment in oesophageal and other cancer

CYTOFLOC: Cytosponge™ for post‐chemoradiation surveillance of oesophageal cancer

CYTOFLOC: Cytosponge™ for post‐chemoradiation surveillance of oesophageal cancer

FRONTIER: Fluciclovine (18F) imaging of breast cancer

FRONTIER: An open-labelled study to characterise Fluciclovine (18F) uptake measured by positron emission tomography in breast cancer

NuTide:301: Safety, pharmacokinetics and clinical activity of NUC-3373, a nucleotide analogue, in participants with advanced solid tumours.

IMAGO: A single arm exploratory study examining the feasibility of imaging glioblastoma pH using CEST MRI

TARDOX: Targeted chemotherapy using focused ultrasound for liver tumours

TARDOX :A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin from Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients with Primary or Secondary Liver Tumours

CAMELLIA: Anti-CD47 antibody terapy in relapsed/refractory Haematological Malignancies

CAMELLIA: A Phase I dose escalation trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Acute Myeloid Leukaemia

ATOM: Atovaquone as Tumour HypOxia Modifier

ATOM: Pre-operative window of opportunity study of the effects of atovaquone on hypoxia in non-small cell lung carcinoma.